Hugo J G Snippert
Overview
Explore the profile of Hugo J G Snippert including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
1089
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Brink G, Hami N, Mertens S, Nijman H, van Lonkhuijzen L, Roes E, et al.
Mol Cancer Ther
. 2024 Nov;
PMID: 39600124
In patients with the rare adult-type granulosa cell tumors (aGCT), surgery is the primary treatment for both primary and recurrent disease. In cases of inoperable disease, systematic therapy is administered,...
2.
Efficacy and safety in early-phase clinical trials for refractory colorectal cancer: A meta-analysis
Smabers L, Huismans M, van Nieuwenhuijzen N, Minnema M, Kranenburg O, Koopman M, et al.
Eur J Cancer
. 2024 Oct;
212:115059.
PMID: 39368225
Background: Despite recent metastatic colorectal cancer (mCRC) therapeutic innovations a comprehensive synthesis of patient outcome and risk-benefit assessment of phase 1/2 trials is missing. The aim of this meta-analysis is...
3.
Kayhanian H, Cross W, van der Horst S, Barmpoutis P, Lakatos E, Caravagna G, et al.
Nat Genet
. 2024 Jul;
56(7):1420-1433.
PMID: 38956208
Mismatch repair (MMR)-deficient cancer evolves through the stepwise erosion of coding homopolymers in target genes. Curiously, the MMR genes MutS homolog 6 (MSH6) and MutS homolog 3 (MSH3) also contain...
4.
Mertens S, Huismans M, Verissimo C, Ponsioen B, Overmeer R, Proost N, et al.
Cell Rep
. 2023 Mar;
42(4):112324.
PMID: 37000626
Patient-derived organoids (PDOs) are widely heralded as a drug-screening platform to develop new anti-cancer therapies. Here, we use a drug-repurposing library to screen PDOs of colorectal cancer (CRC) to identify...
5.
Chen J, Hug C, Reyes J, Tian C, Gerosa L, Frohlich F, et al.
Cell Rep
. 2023 Mar;
42(3):112252.
PMID: 36920903
Oncogene-induced senescence is a phenomenon in which aberrant oncogene expression causes non-transformed cells to enter a non-proliferative state. Cells undergoing oncogenic induction display phenotypic heterogeneity, with some cells senescing and...
6.
Heinz M, Peters N, Oost K, Lindeboom R, van Voorthuijsen L, Fumagalli A, et al.
Cancer Res
. 2022 May;
82(10):1953-1968.
PMID: 35570706
Significance: Characterization of the cell type dynamics, composition, and transcriptome of early colorectal cancer liver metastases reveals that failure to establish cellular heterogeneity through YAP-controlled epithelial self-organization prohibits the outgrowth...
7.
Bollen Y, Hageman J, van Leenen P, Derks L, Ponsioen B, Buissant des Amorie J, et al.
PLoS Biol
. 2022 Jan;
20(1):e3001527.
PMID: 35089911
CRISPR-associated nucleases are powerful tools for precise genome editing of model systems, including human organoids. Current methods describing fluorescent gene tagging in organoids rely on the generation of DNA double-strand...
8.
Bollen Y, Stelloo E, van Leenen P, van den Bos M, Ponsioen B, Lu B, et al.
Nat Genet
. 2021 Jul;
53(8):1187-1195.
PMID: 34211178
Central to tumor evolution is the generation of genetic diversity. However, the extent and patterns by which de novo karyotype alterations emerge and propagate within human tumors are not well...
9.
van Dijk E, van den Bosch T, Lenos K, El Makrini K, Nijman L, van Essen H, et al.
Nat Commun
. 2021 May;
12(1):3188.
PMID: 34045449
Survival rates of cancer patients vary widely within and between malignancies. While genetic aberrations are at the root of all cancers, individual genomic features cannot explain these distinct disease outcomes....
10.
Ponsioen B, Post J, Buissant des Amorie J, Laskaris D, van Ineveld R, Kersten S, et al.
Nat Cell Biol
. 2021 Apr;
23(4):377-390.
PMID: 33795873
Direct targeting of the downstream mitogen-activated protein kinase (MAPK) pathway to suppress extracellular-regulated kinase (ERK) activation in KRAS and BRAF mutant colorectal cancer (CRC) has proven clinically unsuccessful, but promising...